

# Sustainability Report 2024

Peptido GmbH



# Table of Contents

Foreword by the Managing Directors

1. About this Report

2. About Peptido

2.1. Our Company Profile

2.2. Our Mission and Vision

3. Sustainability Strategy

3.1. Material Areas of Action

4. Environment

4.1. Energy and Greenhouse Gas Emissions

4.2. Biodiversity

4.3. Water

4.4. Resource Use, Circular Economy, and Waste Management

5. Social


5.1. Employees: General Characteristics

5.2. Employees: Health and Safety

5.3. Employees: Compensation, Collective Bargaining Agreements, Training

6. Governance

6.1. Convictions and Monetary Fines for Corruption and Money Laundering





# Foreword from Executive Management

Since our founding in 1987, Peptido GmbH has been committed to excellence in the production of high-quality active pharmaceutical ingredients (APIs) for the pharmaceutical industry, consistently guided by the principles of current good manufacturing practice (cGMP) and advanced organic synthesis processes. Our foremost objective is the complete satisfaction of our customers, to whom we offer a comprehensive range of services from laboratory-scale synthesis to commercial manufacturing, including all required analytics, regulatory documentation (CEPs, DMFs), and stability studies. We strive to establish long-term partnerships with our customers through the continuous further development of our products, in order to optimally meet their specific requirements.



Dr. Uwe Wahren  
Managing Director

Dr. Michael Fünfroeken  
Managing Director

As a leader in service and quality, we are committed to sustainable business practices that go far beyond legal requirements. We seek to actively contribute to social justice, environmental protection, and responsible corporate conduct. In doing so, we align ourselves with the United Nations 2030 Agenda for Sustainable Development and its Sustainable Development Goals (SDGs), as well as the UN Guiding Principles on Business and Human Rights. Together with our partners, we work to shape a livable and just future, underpinned by the highest ethical standards, genuine responsibility, and a firm commitment to embedding sustainability in everything we do.

Our mission statement:

M

In our pursuit to improve people’s lives through our high-quality pharmaceutical active ingredients, we recognize the importance of ethical conduct in all aspects of our business activities. Our sustainability strategy aims to align environmental responsibility, social responsibility, and economic performance, thereby making a lasting positive contribution to society and the environment.







# 1. About this Report

This Sustainability Report by Peptido GmbH covers the 2024 calendar year (January 1–December 31, 2024). It is aligned with the 2024 version of the Voluntary Sustainability Reporting Standard for Small- and Medium-Sized Enterprises (VSME) issued by the European Financial Reporting Advisory Group (EFRAG). The VSME translates the core ESG requirements of the Corporate Sustainability Reporting Directive (CSRD) into a streamlined, practice-oriented framework for non-listed small and medium-sized enterprises, making it well suited to the structure and scale of Peptido GmbH. For this first report, we apply the VSME Core Module, which covers the key ESG topic areas:



By applying the Core Module, we collect consistent and comparable key performance indicators that enable data-driven management of our ESG topics and form the basis for the continuous further development of our sustainability strategy. This report marks the starting point for the systematic expansion of our ESG activities and increases transparency for internal and external stakeholders. Unless otherwise stated, the information provided refers to Peptido GmbH.




# 2. About Peptido

## 2.1 Our Company Profile

Peptido GmbH is a medium-sized company based in Bexbach, Germany, that has been manufacturing high-quality active pharmaceutical ingredients (APIs) for the international pharmaceutical industry since 1987. We specialize in organic synthesis under cGMP conditions, with a strong focus on meeting even highly complex requirements quickly, flexibly, and to the highest quality standards. Our many years of experience and international regulatory approvals, including from the U.S. FDA, together with the Certificates of Suitability (CEPs) granted for our products, form the foundation of our work. Supported by a dedicated team of specialists, we reliably guide our customers through all phases of API development – from research and pilot-scale production to commercial manufacturing.

## History



## 2.2 Our Mission and Vision

### Our Vision

*“Peptido strives to be recognized as a leading manufacturer of high-quality and sustainable active pharmaceutical ingredients that meet the highest standards, thereby making a positive contribution to human health and environmental protection.”*

### Our Mission

*“Our mission is to create sustainable value by manufacturing active pharmaceutical ingredients of the highest quality that are precisely aligned with our customers’ needs while conserving the environment. We are committed to integrity, ethics, and compliance with the law, and we foster a culture of collaboration in which our employees can realize their full potential in a safe working environment.”*



# Our Philosophy

Peptido's success stems from the dedication of each individual employee and our shared commitment to putting our guiding principles into practice. Our vision provides clear direction for our daily actions, while our mission translates this long-term ambition into concrete principles that guide decisions, processes, and innovation. We are committed to seven guiding values that define our actions and objectives. Each of these seven values is equally important, and they operate in close interplay with one another. Together, these seven values form the foundation of everything we do and serve as a compass for all employees as we work to fulfill our mission and ensure long-term, sustainable success. They are not only an integral part of our corporate culture but have also been symbolically reflected in our logo for decades.

## Products

P

We strive to offer active pharmaceutical ingredients that are not only of the highest quality but are also the result of our continuous efforts to find new ways to overcome challenges and create added value for our customers. Drawing on our decades of experience in API manufacturing and the ongoing advancement and modernization of our production, we provide our customers with APIs that give them a decisive competitive edge.

## Customer Focus

C

Our customers are at the center of everything we do. We strive to understand their needs and provide tailored solutions. Through active listening, open communication, and first-class customer service and reliable delivery performance, we build long-term partnerships founded on trust and mutual success.

## Employee Engagement & Occupational Safety

E

Our employees are our most valuable asset. We foster a culture of collaboration, respect, and commitment that enables each individual to realize their full potential. Through continuous training, professional development opportunities, and a safe working environment, we create an atmosphere in which our employees can thrive and succeed. The safety and well-being of our employees are our top priority. We are committed to taking all necessary measures to ensure that our workplaces are safe and free from health risks. Through training, risk assessments, and regular reviews, we strive for the continuous improvement of our occupational health and safety standards.

## Quality

Q

We are committed to supplying active pharmaceutical ingredients that meet the highest standards and exceed our customers' expectations. Through rigorous quality control and continuous improvement, we ensure the reliability and safety of our active ingredients.

## Sustainability

S

We recognize our responsibility toward the environment and future generations. That is why we integrate sustainable practices into all aspects of our business – from procurement and product development to manufacturing and disposal. We strive to use resources efficiently and minimize environmental impacts by also aligning our supply chains with sustainability and social responsibility.

## Integrity & Ethics

I

We always act on the basis of honesty, integrity, and ethical conduct. We comply with all applicable laws and regulations and never compromise on our ethical standards. Through transparent business practices and responsible behavior, we strengthen the trust of our stakeholders and build long-term relationships with our business partners.

## Compliance

C

We are committed to complying with all applicable laws, regulations, and standards in every area of our business. We foster a culture of legality and compliance and implement clear policies and training to ensure that all employees understand and adhere to the relevant laws.





# 3. Sustainability Strategy

## 3.1 Material Areas of Action

Sustainability is not an add-on, but an integral part of our seven corporate values. On this basis, we assume responsibility for the environment, people, and our business partners along the entire value chain. Our strategy is built on two pillars:



### Legal Compliance:

We strictly adhere to all relevant laws and regulations, from cGMP guidelines and occupational health and safety requirements to human rights and environmental regulations.

### Corporate Philosophy:

Our vision and mission anchor sustainability as a core objective; our seven core values (quality, product innovation, customer focus, employee engagement & occupational safety, sustainability, integrity & ethics, and compliance) define our framework for action.

### Our sustainability strategy is designed to be adaptable:

We promptly incorporate legislative changes, new scientific findings, or customer requirements into our processes and targets. Our annual Sustainability Report serves as a management tool, makes progress transparent, and sets new milestones—always guided by our mission of “manufacturing health-promoting active ingredients while protecting the environment.”

### Our strategic priorities and planned measures at a glance:

#### Environment

In manufacturing our active pharmaceutical ingredients, we are committed to continuously reducing energy consumption, sourcing raw and auxiliary materials sustainably, and avoiding or recycling waste wherever possible.

Targets for 2025:

**Sustainable procurement:** Implementation of a binding procurement policy

**Own power generation:** Expansion of in-house photovoltaic capacity

**Reduction of water consumption:** Ongoing reduction and increased reuse of water

#### Social

Our qualified employees are the heart of Peptido. We create a safe, healthy, and diverse working environment, ensure fair compensation, and open up individual development opportunities.

#### Governance

Peptido operates with clearly defined structures, transparent processes, and well-defined responsibilities. Our ambition is to be a fair, reliable, and trustworthy partner for customers, business partners, and employees alike.

### Targets for 2025:

**Code of Conduct:** Introduction of a company-wide Code of Conduct that sets binding rules on integrity, anti-corruption, and compliance

**Supplier Code of Conduct:** Introduction of a company-wide Supplier Code of Conduct that defines binding standards on ethical behavior, human rights, working conditions, and environmental protection along the supply chain

**External whistleblowing hotline:** Establishment of a reporting channel that allows anonymous reporting without retaliation and ensures transparent follow-up

**Sustainability Report:** Annual publication to disclose progress and define new targets



Our sustainability strategy is aligned with the 17 Sustainable Development Goals (SDGs) of the United Nations. While each goal is important, our measures particularly contribute to the SDGs in the following ways:



**By developing safe and effective active pharmaceutical ingredients**



**By providing vocational training and continuous professional development for our employees**



**By ensuring fair working conditions and fostering long-term employee retention**



**By ensuring fair working conditions and fostering long-term employee retention**



**By implementing measures to reduce CO<sub>2</sub> emissions and increase energy efficiency**

In doing so, we secure long-term economic success, strengthen the trust of our stakeholders, and make an active contribution to the global sustainability goals.





# 4. Environment

As a manufacturer of active pharmaceutical ingredients (APIs), we impact the environment primarily through our energy and water consumption as well as our waste streams. We are fully aware of our environmental responsibility. Therefore, in addition to this Sustainability Report, we prepare a separate Environmental Report every year. In this report, we analyze all relevant key figures and compare them with the previous year's data. The indicators recorded include total energy consumption, total water consumption, total gas consumption, and the total weight of hazardous and non-hazardous waste.

On this basis, we continuously develop projects to reduce our environmental footprint without compromising the strict quality and safety requirements of API production, and we use these insights to define the measures presented in this Sustainability Report.




## 4.1 Energy and Greenhouse Gas Emissions

In line with our Environmental Report, we regularly measure and analyze our energy consumption in order to identify potential savings and opportunities for improvement. This section provides an overview of the development of our energy consumption at our site from 2019 to 2024 and highlights efficiency gains as well as the impact of ongoing measures to reduce our energy use.

In the reporting year 2024, 68% of our site's energy consumption was attributable to electricity, 30% to natural gas, and 2% to fuel for the vehicle fleet. Electricity thus accounts for the largest share of total consumption, while the use of natural gas is subject primarily to seasonal fluctuations and has only a minor impact on production processes. Our company car fleet includes hybrid and electric vehicles, for which appropriate charging stations are available on site.

Distribution of energy sources in 2024 (%)






# Electricity consumption in detail – 2019 to 2024



Annual electricity consumption in percent from 2019 to 2024



Note. The year 2019 serves as the reference value (100%); the subsequent years show relative electricity consumption in comparison.

Annual electricity consumption per quantity of product produced in percent from 2019 to 2024



Note. The year 2019 serves as the reference value (100%); the subsequent years show relative electricity consumption in comparison.


In 2024, annual electricity consumption remained below the 2019 reference level and declined slightly for the second consecutive year, despite ongoing construction activities. The changes were within a low percentage range. The new production hall was not yet in operation at the time of reporting; once it is commissioned, a higher electricity demand is expected in the medium term. At the same time, modern technologies such as a photovoltaic system, energy-efficient production equipment, and an optimized ventilation system offer potential savings that can offset this additional demand over the long term. During the transition phase, however, a temporarily higher electricity demand is expected, particularly due to the shift from gas to electricity, for example through the use of heat pumps, instantaneous water heaters, or nitrogen generation from compressed air. After commissioning of the new building and in the course of planned scale-up projects, there is additional potential to further increase process efficiency and thus reduce specific energy consumption. In 2024, the efficiency level of the previous year was maintained.

Between 2019 and 2024, annual electricity consumption per unit of product produced decreased, meaning that energy efficiency was continuously improved despite fluctuations in total consumption.



Gas consumption in detail – 2019 to 2024

Annual gas consumption in percent from 2019 to 2024



Note. The year 2019 serves as the reference value (100%); the subsequent years show relative gas consumption in comparison

The increase in gas consumption observed over several years continued and continues to be closely monitored. The comparatively low consumption in 2022 can be attributed to heightened awareness among employees. Awareness-raising measures will remain a central approach to reducing consumption in the future, alongside the transition to electric heat generation.

Since natural gas is not used directly in production and no production-relevant equipment is operated directly with gas, there is only an indirect relationship between gas consumption and production volume. Gas consumption arises primarily from central heat supply, which is used, among other things, to provide hot water for use in production processes as well as for building services. The new building was not yet fully operational at the time of reporting. As gas heating is being phased out there in favor of more environmentally friendly alternatives such as heat pumps, a significant reduction in gas consumption can be expected in the future.

## Greenhouse Gas Inventory

In 2024, we prepared a comprehensive greenhouse gas inventory for the first time, covering both direct emissions (Scope 1) and indirect emissions (Scope 2). The collection and analysis of data were based on a risk-based approach to ensure that all relevant and potentially material emission sources were taken into account. To convert activity data into CO<sub>2</sub> equivalents (CO<sub>2</sub>e), we used the “ecocockpit” accounting tool provided by Effizienz-Agentur NRW. The emission factors were taken from recognized sources such as the German Environment Agency (UBA) and supplemented by specific factors from the respective energy suppliers. The reported emissions are consistent with the requirements of the Greenhouse Gas Protocol.

For the future, we plan to also record Scope 3 emissions, including, for example, raw materials, business travel, and disposal routes, in order to capture a complete emissions profile and identify additional reduction potentials.



In 2024, our company generated a total of 586.96 metric tons of CO<sub>2</sub>e from direct emissions (Scope 1) and indirect emissions from purchased energy (Scope 2). For comparison, a single long-haul flight from Frankfurt to New York emits, according to figures from atmosfair and the International Civil Aviation Organization (ICAO)—depending on aircraft type and load factor—between 600 and 800 metric tons of CO<sub>2</sub>e. Our total annual emissions are therefore lower than those of a single transatlantic flight. This comparison illustrates that our company already operates with a comparatively low emissions profile and achieves efficient resource use in its ongoing operations.



# Outlook for 2025

Based on the initial greenhouse gas inventory, specific reduction targets will be defined for 2025. Planned measures include:

**Heat pumps in the new building:**

The planned transition to heat pumps in the new building will further reduce natural gas consumption.

**LED retrofits and motion sensors:**

Lighting in the office buildings will be gradually converted to LED technology in order to reduce electricity consumption. In addition, more motion sensors will be installed so that lighting is only activated when needed, thereby saving additional energy.

**Photovoltaic system: A photovoltaic**

system will be installed on the new building, enabling us to generate part of the required electricity on-site, reduce dependence on external electricity suppliers, and lower CO<sub>2</sub> emissions.

**Heat recovery for exhaust and supply air:**

A heat recovery system will be installed that uses the waste heat from exhaust air to preheat the supply air for the production hall. This reduces energy demand, as less external energy is required to heat the incoming air.

**Heat recovery in heating/cooling systems:**

In production equipment, particularly heating and cooling systems, a heat recovery system will be integrated. The heat generated will be recovered and fed into the heating system, further reducing energy consumption.

These measures to improve energy efficiency and conserve resources are strategically planned and contribute to reducing overall energy consumption and CO<sub>2</sub> emissions. In the short term, an increase in electricity demand is expected due to the commissioning of new production facilities. In the medium term, however, total energy consumption is to be reduced through on-site power generation and efficiency measures, with an increased use of renewable energy sources.





## 4.2 Biodiversity

Peptido does not operate any sites in ecologically or biodiversity-sensitive areas and does not plan to establish operations in such regions in the future.


## 4.3 Water

According to the Aqueduct Water Risk Atlas, Peptido’s site is not located in a region with high water stress. In line with our Environmental Report, water consumption is continuously recorded and evaluated on an annual basis. Responsible use of this resource is essential for us, even though savings potential is limited, as the generation of purified water required for our production processes necessitates large amounts of drinking water.

**Wastewater disposal:** Production wastewater is collected separately, picked up by a certified specialist company, and disposed of properly.

### Water consumption in detail – 2019 to 2024

Annual water consumption in percent from 2019 to 2024



*Note. The year 2019 serves as the reference value (100%); the subsequent years show relative water consumption in comparison.*

The upward trend in water consumption observed in the previous year did not continue in 2024. Total consumption remained at the 2023 level, maintaining a significant reduction compared with the 2019 reference year.

Consumption was evenly distributed over the year. Cost efficiency and process efficiency were also maintained at a level that remains significantly improved compared with 2019. In the coming years, water consumption is expected to increase in connection with the commissioning of the new production building. Further significant reductions in consumption are only possible to a limited extent due to already optimized production processes, although smaller improvements remain feasible.

## 4.4 Resource Use, Circular Economy, and Waste Management

Peptido is committed to the principles of the circular economy in order to minimize waste and keep resources within the material cycle. This includes measures for waste prevention, reuse, and recycling. One example is the shipment of iodine-containing waste for iodine recovery and its use in other areas for renewed industrial applications, thereby conserving resources and reducing disposal efforts. The waste data we evaluate annually serve as a management tool to further reduce waste volumes:






# Waste Streams in Detail - 2019 to 2024




Annual ADR waste streams in percent from 2019 to 2024



Note. The year 2019 serves as the reference value (100%); the subsequent years show relative ADR waste streams in comparison.

At Peptido, ADR waste streams are distributed across dangerous goods classes 3 (flammable liquids), 6 (toxic substances), and 8 (corrosive substances). Initial product quality optimizations led to higher waste streams. However, ongoing optimization of production processes is continuously aimed at reducing ADR waste streams. In 2023, the total volume of ADR waste streams, relative to the quantity of product manufactured, was lower than in the previous year for the first time. Additional optimization potential is currently being evaluated.

Annual waste streams in percent from 2019 to 2024



Hazardous waste is clearly labeled, stored separately, and disposed of exclusively by certified specialist companies. All employees are trained in the safe handling of hazardous substances.

ADR waste streams and non-dangerous-goods waste streams per quantity of product manufactured

ADR waste streams per quantity of product manufactured

Non-dangerous-goods waste streams per quantity of product manufactured






# Commercial Waste in Detail - 2019 to 2024



Annual commercial waste in percent from 2019 to 2024



*Note. The year 2019 serves as the reference value (100%); the subsequent years show relative commercial waste volumes in comparison.*

Commercial waste arises predominantly from packaging materials. The volume of this waste can only be influenced to a limited extent, as many raw materials are delivered in pre-packaged form, which makes an important contribution to employee safety and GMP compliance.

Commercial waste has shown a moderate but steady increase over the reporting period. For 2025, separate collection is planned: with the new building and the commissioning of the new production line, packaging materials will be collected separately and sent for recycling.





# 5. Social – Employees


Peptido provides a working environment that equally promotes safety, health, and personal development. Our employees are at the center of this approach: transparent communication, flat hierarchies, and the close involvement of the works council enable a trusting and constructive collaboration. To ensure occupational health and safety, a formalized process has been established that systematically assesses and documents potential risks before new or modified work processes are introduced.

In addition, the Occupational Safety Committee meets quarterly to analyze incidents and risks and to define appropriate measures. Regular safety instructions, the provision of necessary personal protective equipment, and support from an external occupational physician are integral components of our occupational safety concept. Safety data sheets are available to all employees.

Employment relationships at Peptido GmbH are governed by written contracts; weekly working hours, vacation, and overtime arrangements are clearly defined. Overtime is recorded and compensated with time off in lieu, while work on Sundays and public holidays is remunerated with appropriate premiums. New hires are made on the basis of a defined work instruction and with the involvement of the works council. A systematic collection and reporting of key figures on employee health and safety is not yet implemented.

## 5.1 Employees: General Characteristics

As of December 31, 2024, Peptido employed 45 full-time equivalents (FTE): 43 FTE on permanent contracts and 2 FTE on fixed-term contracts. The workforce consisted of 32 male and 13 female employees. Peptido employs only its own staff and does not use temporary agency workers. The company operates exclusively in Germany; therefore, no information is reported on employment contracts in other countries.



## 5.2 Employees: Health & Safety

In 2024, a total of one notifiable occupational accident was recorded at Peptido. There were no work-related fatalities or deaths resulting from occupational illnesses. To systematically prevent workplace accidents, the Occupational Safety Committee meets quarterly. The committee consists of Production Management, the Works Council, and Executive Management, together with an external occupational safety specialist and the company physician. In these meetings, accidents are reviewed, root causes are analyzed, and appropriate corrective measures are decided.

All employees are provided with the necessary personal protective equipment. In addition, we conduct regular safety trainings, including mandatory annual trainings on ergonomic working practices, safe lifting and carrying, and handling hazardous substances. Peptido currently has eight trained first aiders and 14 trained fire safety assistants, who can respond quickly in emergencies and help prevent harm to people and facilities until professional emergency services arrive.

|                                     | Unit                      | Indicator |
|-------------------------------------|---------------------------|-----------|
| Work-related accidents (notifiable) | Number                    | 1         |
| Accident rate*                      | Per 200,000 working hours | ~ 2.5     |
| Fatalities                          | Number                    | 0         |

Note: Formula: notifiable work-related accidents / hours worked × 200,000 (OSHA standard).



## 5.3 Employees: Compensation, Collective Agreements & Training

Peptido pays all employees above the statutory minimum wage and supplements base salaries with an employer-funded company pension plan and employee savings schemes. Although Peptido is not bound by collective bargaining agreements, non-tariff salaries are aligned with transparent industry benchmarks and performance-based criteria. Regardless of gender, equal pay is granted for work of equal value, and there are no pay differentials.

An elected works council represents the interests of all employees and reviews all relevant hiring decisions and working time arrangements. Peptido actively supports a balanced work-life relationship: flexible working time models, timely time-off in lieu for overtime, and home office options help employees reconcile professional and personal responsibilities. Weekly working hours and vacation entitlements are defined in a binding work instruction that also covers overtime and its compensation through time off in lieu, as well as additional pay for atypical working hours and work on public holidays.


### Training and Vocational Education

Since 1994, Peptido has been a recognized training company accredited by the Chamber of Industry and Commerce (IHK) and is continuously committed to the qualification and further development of its employees. In addition to providing apprenticeship positions in technical/industrial and commercial occupations, the company supports individual advanced training and professional development measures in coordination with the respective line manager.


In the 2024 reporting year, annual training hours per full-time equivalent (FTE) were systematically recorded and analyzed in a differentiated manner—for example by gender, type of training, and whether participation was voluntary or mandatory. In addition to mandatory trainings, a wide range of internal and external courses on GMP, EHS, and other specialized topics took place.

In addition, event- and department-specific trainings were conducted, for example in the context of process changes or the implementation of new regulatory requirements. The following overview provides a detailed insight into the distribution of average training hours per employee for the year 2024.


#### Mandatory training




#### Advanced training (internal)



#### Advanced training (external)



#### Total



*Note: The figure shows the average annual training hours per employee, broken down by gender.*



# 6. Governance

## 6.1 Convictions and Fines for Corruption and Money Laundering

Lawful and rule-compliant conduct is the foundation of our business success. Only by operating independently and consistently in full compliance with all applicable laws and regulations of the Federal Republic of Germany can we create sustainable value for our customers and partners. In the 2024 reporting year, no proceedings for corruption or bribery were initiated against Peptido, and no fines were imposed.

To further strengthen this commitment going forward, we are currently working on two key governance elements that will be fully implemented as of 2025:



I.     **Company-wide Code of Conduct**

The Code will prohibit any form of undue advantage, bribery, and anti-competitive behavior. It will be binding for all employees and will be embedded through mandatory training as well as a publicly accessible version on our website.



II.    **External whistleblowing hotline**

The hotline will enable both internal and external whistleblowers to report suspected violations anonymously and without fear of retaliation. All reports will be reviewed confidentially and, where necessary, addressed with consistent but fair sanctions. At present, clearly defined responsibilities and approval procedures, an internal reporting mechanism, and the involvement of the works council ensure compliance with our internal and external requirements.





# Contact

Am Kraftwerk 6  
D-66450 Bexbach  
Phone: +49-(0)6826 / 9358-100  
Fax: +49-(0)6826 / 9358-200  
Website: [www.peptido.de](http://www.peptido.de)  
E-Mail: [info@peptido.de](mailto:info@peptido.de)

Dr. Michael Fünfroeken  
Managing Director  
[michael.fuenfroeken@peptido.de](mailto:michael.fuenfroeken@peptido.de)

Dr. Uwe Wahren  
Managing Director  
[uwe.wahren@peptido.de](mailto:uwe.wahren@peptido.de)

**peptido**  
1 2 3 4 5 6 7

active substances

*As of August 2025*